MX2023008075A - Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre. - Google Patents

Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.

Info

Publication number
MX2023008075A
MX2023008075A MX2023008075A MX2023008075A MX2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A MX 2023008075 A MX2023008075 A MX 2023008075A
Authority
MX
Mexico
Prior art keywords
dosage regimens
antibodies
dendritic cell
cell antigen
pharmaceutical compositions
Prior art date
Application number
MX2023008075A
Other languages
English (en)
Inventor
David Martin
David Dai
Shantanu Sule
Dania Rabah
Mark R H Krebs
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2023008075A publication Critical patent/MX2023008075A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan formulaciones y regímenes de dosificación de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre (BDCA2). Estas formulaciones y regímenes de dosificación se usan en el tratamiento de trastornos asociados al BDCA2 tales como el lupus eritematoso sistémico, lupus eritematoso cutáneo y lupus eritematoso discoide, así como el síndrome de liberación de citocinas.
MX2023008075A 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre. MX2023008075A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28

Publications (1)

Publication Number Publication Date
MX2023008075A true MX2023008075A (es) 2023-07-18

Family

ID=58672794

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012945A MX2018012945A (es) 2016-04-28 2017-04-27 Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.
MX2023008075A MX2023008075A (es) 2016-04-28 2018-10-23 Composiciones farmaceuticas y regimenes de dosificacion para uso clinico de anticuerpos del antigeno 2 de las celulas dendriticas de la sangre.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018012945A MX2018012945A (es) 2016-04-28 2017-04-27 Composiciones farmacéuticas y regímenes de dosificación para uso clínico de anticuerpos del antigeno 2 de las células dendríticas de la sangre.

Country Status (15)

Country Link
US (1) US20190284281A1 (es)
EP (1) EP3448425A1 (es)
JP (3) JP7045327B2 (es)
KR (3) KR102366547B1 (es)
CN (2) CN116850282A (es)
AU (1) AU2017258191A1 (es)
BR (1) BR112018072125A2 (es)
CA (1) CA3022116A1 (es)
CO (1) CO2018012506A2 (es)
EA (1) EA201892443A1 (es)
IL (1) IL262514A (es)
MA (1) MA44763A (es)
MX (2) MX2018012945A (es)
PH (1) PH12018502278A1 (es)
WO (1) WO2017189827A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
US20240018246A1 (en) 2020-12-03 2024-01-18 Biogen Ma Inc. Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
AU2022327892A1 (en) 2021-08-09 2024-03-28 Inventera Inc. Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
KR102344907B1 (ko) * 2012-12-10 2021-12-28 바이오젠 엠에이 인코포레이티드 항-혈액 수지상 세포 항원 2 항체 및 이의 용도

Also Published As

Publication number Publication date
KR102366547B1 (ko) 2022-02-23
IL262514A (en) 2018-12-31
CN109475623A (zh) 2019-03-15
KR20190002563A (ko) 2019-01-08
KR20240033168A (ko) 2024-03-12
US20190284281A1 (en) 2019-09-19
MX2018012945A (es) 2019-03-06
JP2019520316A (ja) 2019-07-18
CN116850282A (zh) 2023-10-10
CO2018012506A2 (es) 2018-12-14
JP2024038308A (ja) 2024-03-19
MA44763A (fr) 2019-03-06
AU2017258191A1 (en) 2018-11-15
EA201892443A1 (ru) 2019-04-30
CA3022116A1 (en) 2017-11-02
PH12018502278A1 (en) 2019-09-09
WO2017189827A1 (en) 2017-11-02
KR20220028150A (ko) 2022-03-08
JP7045327B2 (ja) 2022-03-31
EP3448425A1 (en) 2019-03-06
CN109475623B (zh) 2023-05-26
BR112018072125A2 (pt) 2019-03-19
JP2022084782A (ja) 2022-06-07

Similar Documents

Publication Publication Date Title
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
PH12020500238A1 (en) Cytokine conjugates for the treatment of proliferative and infectious diseases
PH12017500803A1 (en) Anti-pd-1 antibodies
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2016081518A3 (en) Engineered gamma delta t-cells
WO2018075857A8 (en) Novel cd47 monoclonal antibodies and uses thereof
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
WO2016105542A3 (en) Nanoparticle compositions and methods for immunotherapy
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2019001308A (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos.
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019001319A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
WO2016004213A3 (en) Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2015002620A1 (es) Derivados piridin-4-ilo
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.